These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36470427)

  • 1. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
    Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
    J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
    Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
    EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Binds to B7-1 Only
    Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
    Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restriction of PD-1 function by
    Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
    Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.
    Abdolmaleki S; Ganjalikhani Hakemi M; Ganjalikhany MR
    PLoS One; 2024; 19(7):e0304270. PubMed ID: 39052609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.
    Sugiura D; Okazaki IM; Maeda TK; Maruhashi T; Shimizu K; Arakaki R; Takemoto T; Ishimaru N; Okazaki T
    Nat Immunol; 2022 Mar; 23(3):399-410. PubMed ID: 35145298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
    Córdova-Bahena L; Velasco-Velázquez MA
    Rev Invest Clin; 2020 Oct; 73(1):008-016. PubMed ID: 33079077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and interactions of the human programmed cell death 1 receptor.
    Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
    J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
    Roither B; Oostenbrink C; Schreiner W
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
    Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
    Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
    Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence-specific
    Walker K; Waters LC; Kelly G; Muskett FW; Carr MD
    Biomol NMR Assign; 2022 Oct; 16(2):281-288. PubMed ID: 35675028
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Reddy VRAP; Mwangi W; Sadigh Y; Nair V
    Front Cell Infect Microbiol; 2019; 9():436. PubMed ID: 31921710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
    Jiang Y; Hong K; Zhao Y; Xu K
    Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.